Sanara MedTech Stock Forum

Sanara MedTech's balance sheet is strained due to liabilities and lack of profitability. Its use of debt is risky, given its negative EBIT and free cash flow. However, its top-line growth is viewed positively.

Sanara MedTech's high P/S ratio is justified by its strong forecasted revenue growth, according to investor sentiment.

Analysts anticipate breakeven for Sanara MedTech within a year, indicating bullish outlook. The prospects hinge on company's maintenance of robust 225% annual growth rate. The firm's low debt, majorly equity-funded, reduces investment risk.